about
Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer.Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.Optimizing single agent panitumumab therapy in pre-treated advanced colorectal cancer.Ifosfamide in the adjuvant therapy of soft tissue sarcomas.Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategiesHLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.Confirmed Activity and Tolerability of Weekly Paclitaxel in the Treatment of Advanced Angiosarcoma.Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy.Role of genetic polymorphisms and mutations in colorectal cancer therapy (Review).Malignant cardiac tumors: diagnosis and treatment.Morphologic shift associated with aberrant cytokeratin expression in a GIST patient after tyrosine kinase inhibitors therapy. A case report with a brief review of the literature.Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group.Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.Somatostatin receptor scintigraphy versus chromogranin A assay in the management of patients with neuroendocrine tumors of different types: clinical role.FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy].Improved outcome with multimodal treatment and imatinib rechallenge in advanced GISTFOLFOX2 regimen in the treatment of advanced colorectal cancer: a comparison between elderly and young patientsEffort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated riskPhase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patientsExocrine and Endocrine Modulation in Common Gastric CarcinomaNeoplastic pericardial disease in lung cancer: Impact on outcomes of different treatment strategies. A multicenter studyThe Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal CancerSolid pseudopapillary tumour of the pancreasPrognostic factors in soft tissue sarcomas: a study of 395 patientsAntithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients
P50
Q33329539-D718B893-69CC-413E-AA7A-0227F139C98BQ34444495-EEC7B633-447C-4132-84B1-AAB3E249B0E9Q34528276-31AD7142-49DD-489D-BF5D-866BCCD8B228Q34542947-5F3CE8C2-ACB5-4F00-BA99-31274AA3D333Q34975510-403040DA-10A8-448D-B84C-A75A91B76009Q35082647-BBEEE6EB-2629-44B3-A32A-B4A21A747147Q35569457-AA165DD9-E6E7-40AF-B183-29C53C05FF18Q35860201-4AF46150-7EFE-42E6-98FA-F29F835FE6C0Q36670859-310B34B0-3BEB-4BB1-BDD3-19C9D233B3F2Q36915163-349A0B75-8400-4259-A007-7DE2B3EEC3DAQ37190172-C8D0DAA2-1E50-4925-8E4C-5A667FAE62F3Q37537926-2E44F70C-B830-4E89-A03B-EC34B978B80DQ37862111-EA3DF83E-8C32-4EA8-AE9A-3DAAD2594598Q38559451-7A359552-8825-408A-9246-B42AB764287CQ38652054-A7E188C5-5993-45D8-93AD-ECBE007DAC0AQ40811026-1862EA17-129D-4BC5-A885-45688BEF99B6Q41652822-F87AAAE5-05FA-4ACB-AEAA-D486017479B6Q44481728-F613F858-671A-401E-B89D-4CFE021169CDQ45563347-E58551E6-ABDB-4234-8C85-6297ED84ABF1Q46735031-EC23FA1A-7B4F-463B-A54C-1E5853AC09B8Q47770029-F8B3261F-1022-4EA2-92B9-D6E71FD86A86Q53179257-ECB5C0BE-247A-404D-8A25-D9FFA38A5069Q53497971-A846EEF3-C2CA-479C-83DE-10977A346F25Q58200823-9F4665EB-1C8B-4D04-9DB3-0B424FDC4658Q59388215-36624B52-7D7F-48F9-9A29-39FB76A8D84CQ60697869-696E3386-0311-4813-B363-D512D2D1D98AQ60697885-8C806389-5FE5-4BCA-8085-BEF59A5B521BQ60697886-7D925A67-531E-4A86-8E26-2A9470191ABBQ60697887-00336E21-9E5A-467B-BBDF-2E8BFBB1D77CQ60697890-C480B0F8-8B40-49B1-96C0-909693FBDB7FQ60697912-57AB9A41-1DBA-408D-BE35-B7D4FD391ABAQ60697914-7851C9E5-9458-43B5-8BF4-17A3FC296558Q60697932-67EE0DED-C7A8-438A-B217-315B12124EE4
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Angela Buonadonna
@ast
Angela Buonadonna
@en
Angela Buonadonna
@es
Angela Buonadonna
@nl
Angela Buonadonna
@sl
type
label
Angela Buonadonna
@ast
Angela Buonadonna
@en
Angela Buonadonna
@es
Angela Buonadonna
@nl
Angela Buonadonna
@sl
prefLabel
Angela Buonadonna
@ast
Angela Buonadonna
@en
Angela Buonadonna
@es
Angela Buonadonna
@nl
Angela Buonadonna
@sl
P106
P1153
6701834176
P21
P31
P496
0000-0002-1930-0308